[
  {"year": 2020, "company": "Sensei Biotherapeutics", "ticker": "SNSE", "date": "2020-02-04", "area": "Immuno-Oncology", "offer": 16.0, "proceeds": 104.0, "pricing": "At", "status": "Inline", "phase": "Phase 1", "range_lo": null, "range_hi": null, "ipo_status": "active"},
  {"year": 2020, "company": "Beam Therapeutics", "ticker": "BEAM", "date": "2020-02-06", "area": "Gene Editing", "offer": 17.0, "proceeds": 180.0, "pricing": "At", "status": "Inline", "phase": "Phase 1", "range_lo": null, "range_hi": null, "ipo_status": "active"},
  {"year": 2020, "company": "Passage Bio", "ticker": "PASG", "date": "2020-02-28", "area": "Gene Therapy", "offer": 18.0, "proceeds": 234.0, "pricing": "Above", "status": "Upsized", "phase": "Phase 1", "range_lo": null, "range_hi": null, "ipo_status": "active"},
  {"year": 2020, "company": "Zentalis Pharmaceuticals", "ticker": "ZNTL", "date": "2020-04-03", "area": "Oncology", "offer": 18.0, "proceeds": 174.0, "pricing": "Above", "status": "Upsized", "phase": "Phase 2", "range_lo": null, "range_hi": null, "ipo_status": "active"},
  {"year": 2020, "company": "Generation Bio", "ticker": "GBIO", "date": "2020-06-12", "area": "Gene Therapy", "offer": 20.0, "proceeds": 230.0, "pricing": "Above", "status": "Upsized", "phase": "Preclinical", "range_lo": null, "range_hi": null, "ipo_status": "active"},
  {"year": 2020, "company": "Relay Therapeutics", "ticker": "RLAY", "date": "2020-07-16", "area": "Oncology", "offer": 20.0, "proceeds": 460.0, "pricing": "Above", "status": "Upsized", "phase": "Phase 1", "range_lo": null, "range_hi": null, "ipo_status": "active"},
  {"year": 2020, "company": "ALX Oncology", "ticker": "ALXO", "date": "2020-07-17", "area": "Immuno-Oncology", "offer": 19.0, "proceeds": 168.0, "pricing": "Above", "status": "Upsized", "phase": "Phase 1", "range_lo": null, "range_hi": null, "ipo_status": "active"},
  {"year": 2020, "company": "iTeos Therapeutics", "ticker": "ITOS", "date": "2020-07-17", "area": "Immuno-Oncology", "offer": 19.0, "proceeds": 201.0, "pricing": "Above", "status": "Upsized", "phase": "Phase 2", "range_lo": null, "range_hi": null, "ipo_status": "active"},
  {"year": 2020, "company": "Inhibrx", "ticker": "INBX", "date": "2020-08-19", "area": "Oncology / Rare", "offer": 17.0, "proceeds": 141.0, "pricing": "At", "status": "Inline", "phase": "Phase 1", "range_lo": null, "range_hi": null, "ipo_status": "active"},
  {"year": 2020, "company": "CureVac", "ticker": "CVAC", "date": "2020-08-14", "area": "mRNA / Vaccines", "offer": 16.0, "proceeds": 245.0, "pricing": "At", "status": "Inline", "phase": "Phase 2", "range_lo": null, "range_hi": null, "ipo_status": "active"},
  {"year": 2020, "company": "PMV Pharmaceuticals", "ticker": "PMVP", "date": "2020-09-25", "area": "Oncology", "offer": 18.0, "proceeds": 200.0, "pricing": "Above", "status": "Upsized", "phase": "Phase 1", "range_lo": null, "range_hi": null, "ipo_status": "active"},
  {"year": 2020, "company": "Prelude Therapeutics", "ticker": "PRLD", "date": "2020-09-25", "area": "Oncology", "offer": 27.0, "proceeds": 223.0, "pricing": "Above", "status": "Upsized", "phase": "Phase 2", "range_lo": null, "range_hi": null, "ipo_status": "active"},
  {"year": 2020, "company": "Kinnate Biopharma", "ticker": "KNTE", "date": "2020-11-20", "area": "Oncology", "offer": 24.0, "proceeds": 230.0, "pricing": "Above", "status": "Upsized", "phase": "Phase 1", "range_lo": null, "range_hi": null, "ipo_status": "active"},
  {"year": 2020, "company": "AbCellera Biologics", "ticker": "ABCL", "date": "2020-12-11", "area": "Antibody Discovery", "offer": 20.0, "proceeds": 483.0, "pricing": "Above", "status": "Upsized", "phase": "Commercial", "range_lo": null, "range_hi": null, "ipo_status": "active"},
  {"year": 2021, "company": "Olema Pharmaceuticals", "ticker": "OLMA", "date": "2021-02-05", "area": "Oncology", "offer": 19.0, "proceeds": 208.0, "pricing": "Above", "status": "Upsized", "phase": "Phase 2", "range_lo": null, "range_hi": null, "ipo_status": "active"},
  {"year": 2021, "company": "Sana Biotechnology", "ticker": "SANA", "date": "2021-02-04", "area": "Cell / Gene Therapy", "offer": 25.0, "proceeds": 588.0, "pricing": "Above", "status": "Upsized", "phase": "Preclinical", "range_lo": null, "range_hi": null, "ipo_status": "active"},
  {"year": 2021, "company": "Forte Biosciences", "ticker": "FBRX", "date": "2021-03-19", "area": "Dermatology", "offer": 16.0, "proceeds": 75.0, "pricing": "At", "status": "Inline", "phase": "Phase 2", "range_lo": null, "range_hi": null, "ipo_status": "active"},
  {"year": 2021, "company": "Instil Bio", "ticker": "TIL", "date": "2021-03-19", "area": "Cell Therapy / Oncology", "offer": 20.0, "proceeds": 319.0, "pricing": "Above", "status": "Upsized", "phase": "Phase 2", "range_lo": null, "range_hi": null, "ipo_status": "active"},
  {"year": 2021, "company": "Ikena Oncology", "ticker": "IKNA", "date": "2021-03-19", "area": "Oncology", "offer": 16.0, "proceeds": 155.0, "pricing": "At", "status": "Inline", "phase": "Phase 1", "range_lo": null, "range_hi": null, "ipo_status": "active"},
  {"year": 2021, "company": "Design Therapeutics", "ticker": "DSGN", "date": "2021-03-26", "area": "Genetic Medicine", "offer": 20.0, "proceeds": 276.0, "pricing": "Above", "status": "Upsized", "phase": "Preclinical", "range_lo": null, "range_hi": null, "ipo_status": "active"},
  {"year": 2021, "company": "Recursion Pharmaceuticals", "ticker": "RXRX", "date": "2021-04-16", "area": "AI Drug Discovery", "offer": 18.0, "proceeds": 436.0, "pricing": "At", "status": "Upsized", "phase": "Phase 2", "range_lo": null, "range_hi": null, "ipo_status": "active"},
  {"year": 2021, "company": "Verve Therapeutics", "ticker": "VERV", "date": "2021-06-17", "area": "Cardiovascular / Gene Editing", "offer": 19.0, "proceeds": 307.0, "pricing": "Above", "status": "Upsized", "phase": "Phase 1", "range_lo": null, "range_hi": null, "ipo_status": "active"},
  {"year": 2021, "company": "Lyell Immunopharma", "ticker": "LYEL", "date": "2021-06-18", "area": "Cell Therapy", "offer": 17.0, "proceeds": 425.0, "pricing": "At", "status": "Upsized", "phase": "Preclinical", "range_lo": null, "range_hi": null, "ipo_status": "active"},
  {"year": 2021, "company": "Erasca", "ticker": "ERAS", "date": "2021-07-16", "area": "Oncology", "offer": 16.0, "proceeds": 333.0, "pricing": "At", "status": "Upsized", "phase": "Phase 1", "range_lo": null, "range_hi": null, "ipo_status": "active"},
  {"year": 2021, "company": "Imago BioSciences", "ticker": "IMGO", "date": "2021-07-16", "area": "Hematology", "offer": 16.0, "proceeds": 148.0, "pricing": "At", "status": "Inline", "phase": "Phase 2", "range_lo": null, "range_hi": null, "ipo_status": "active"},
  {"year": 2021, "company": "Absci Corporation", "ticker": "ABSI", "date": "2021-07-22", "area": "AI Drug Design", "offer": 16.0, "proceeds": 198.0, "pricing": "At", "status": "Inline", "phase": "Preclinical", "range_lo": null, "range_hi": null, "ipo_status": "active"},
  {"year": 2021, "company": "Caribou Biosciences", "ticker": "CRBU", "date": "2021-07-23", "area": "Gene Editing", "offer": 16.0, "proceeds": 304.0, "pricing": "Above", "status": "Upsized", "phase": "Phase 1", "range_lo": null, "range_hi": null, "ipo_status": "active"},
  {"year": 2021, "company": "Tenaya Therapeutics", "ticker": "TNYA", "date": "2021-07-30", "area": "Gene Therapy / Cardiology", "offer": 15.0, "proceeds": 173.0, "pricing": "At", "status": "Inline", "phase": "Phase 1", "range_lo": null, "range_hi": null, "ipo_status": "active"},
  {"year": 2022, "company": "Vigil Neuroscience", "ticker": "VIGL", "date": "2022-01-14", "area": "Neuroscience", "offer": 12.0, "proceeds": 83.0, "pricing": "Below", "status": "Inline", "phase": "Phase 1", "range_lo": null, "range_hi": null, "ipo_status": "active"},
  {"year": 2022, "company": "Amylyx Pharmaceuticals", "ticker": "AMLX", "date": "2022-01-07", "area": "Neuroscience (ALS)", "offer": 18.0, "proceeds": 204.0, "pricing": "At", "status": "Inline", "phase": "Approved", "range_lo": null, "range_hi": null, "ipo_status": "active"},
  {"year": 2022, "company": "Arcellx", "ticker": "ACLX", "date": "2022-02-04", "area": "Cell Therapy / Oncology", "offer": 15.0, "proceeds": 124.0, "pricing": "At", "status": "Inline", "phase": "Phase 1", "range_lo": null, "range_hi": null, "ipo_status": "active"},
  {"year": 2022, "company": "Mineralys Therapeutics", "ticker": "MLYS", "date": "2022-10-14", "area": "Cardiometabolic", "offer": 16.0, "proceeds": 192.0, "pricing": "At", "status": "Upsized", "phase": "Phase 2", "range_lo": null, "range_hi": null, "ipo_status": "active"},
  {"year": 2022, "company": "Prime Medicine", "ticker": "PRME", "date": "2022-10-20", "area": "Gene Editing", "offer": 17.0, "proceeds": 175.0, "pricing": "At", "status": "Inline", "phase": "Preclinical", "range_lo": null, "range_hi": null, "ipo_status": "active"},
  {"year": 2023, "company": "Genelux", "ticker": "GNLX", "date": "2023-01-27", "area": "Oncolytic Virus", "offer": 10.0, "proceeds": 15.0, "pricing": "Below", "status": "Inline", "phase": "Phase 2", "range_lo": null, "range_hi": null, "ipo_status": "active"},
  {"year": 2023, "company": "Structure Therapeutics", "ticker": "GPCR", "date": "2023-02-03", "area": "Metabolic / GPCR", "offer": 15.0, "proceeds": 185.0, "pricing": "At", "status": "Inline", "phase": "Phase 2", "range_lo": null, "range_hi": null, "ipo_status": "active"},
  {"year": 2023, "company": "CytoMed Therapeutics", "ticker": "CMED", "date": "2023-04-07", "area": "Cell Therapy", "offer": 4.0, "proceeds": 10.0, "pricing": "Below", "status": "Inline", "phase": "Preclinical", "range_lo": null, "range_hi": null, "ipo_status": "active"},
  {"year": 2023, "company": "Acelyrin", "ticker": "SLRN", "date": "2023-05-05", "area": "Immunology", "offer": 18.0, "proceeds": 540.0, "pricing": "Above", "status": "Upsized", "phase": "Phase 3", "range_lo": null, "range_hi": null, "ipo_status": "active"},
  {"year": 2023, "company": "Abivax", "ticker": "ABVX", "date": "2023-07-14", "area": "GI / Immunology", "offer": 18.0, "proceeds": 236.0, "pricing": "At", "status": "Upsized", "phase": "Phase 3", "range_lo": null, "range_hi": null, "ipo_status": "active"},
  {"year": 2023, "company": "Turnstone Biologics", "ticker": "TSBX", "date": "2023-07-20", "area": "Oncology / Immuno", "offer": 10.0, "proceeds": 60.0, "pricing": "Below", "status": "Inline", "phase": "Phase 2", "range_lo": null, "range_hi": null, "ipo_status": "active"},
  {"year": 2023, "company": "Neumora Therapeutics", "ticker": "NMRA", "date": "2023-09-15", "area": "Neuroscience", "offer": 17.0, "proceeds": 238.0, "pricing": "At", "status": "Inline", "phase": "Phase 3", "range_lo": null, "range_hi": null, "ipo_status": "active"},
  {"year": 2023, "company": "Adlai Nortye", "ticker": "ANL", "date": "2023-09-29", "area": "Oncology", "offer": 10.0, "proceeds": 98.0, "pricing": "At", "status": "Inline", "phase": "Phase 3", "range_lo": null, "range_hi": null, "ipo_status": "active"},
  {"year": 2023, "company": "CARGO Therapeutics", "ticker": "CRGX", "date": "2023-11-10", "area": "Cell Therapy", "offer": 15.0, "proceeds": 281.0, "pricing": "At", "status": "Upsized", "phase": "Phase 2", "range_lo": null, "range_hi": null, "ipo_status": "active"},
  {"year": 2023, "company": "Lexeo Therapeutics", "ticker": "LXEO", "date": "2023-11-17", "area": "Gene Therapy", "offer": 11.0, "proceeds": 100.0, "pricing": "Below", "status": "Inline", "phase": "Phase 1", "range_lo": null, "range_hi": null, "ipo_status": "active"},
  {"year": 2024, "company": "Alto Neuroscience", "ticker": "ANRO", "date": "2024-02-01", "area": "Neuroscience", "offer": 16.0, "proceeds": 132.0, "pricing": "At", "status": "Inline", "phase": "Phase 3", "range_lo": null, "range_hi": null, "ipo_status": "active"},
  {"year": 2024, "company": "Metagenomi", "ticker": "MGX", "date": "2024-02-09", "area": "Gene Editing", "offer": 15.0, "proceeds": 126.0, "pricing": "At", "status": "Inline", "phase": "Phase 1", "range_lo": null, "range_hi": null, "ipo_status": "active"},
  {"year": 2024, "company": "Fractyl Health", "ticker": "GUTS", "date": "2024-02-14", "area": "Metabolic / GI", "offer": 15.0, "proceeds": 112.0, "pricing": "At", "status": "Inline", "phase": "Phase 2", "range_lo": null, "range_hi": null, "ipo_status": "active"},
  {"year": 2024, "company": "Artiva Biotherapeutics", "ticker": "ARTV", "date": "2024-03-22", "area": "Cell Therapy / Oncology", "offer": 12.0, "proceeds": 167.0, "pricing": "Below", "status": "Inline", "phase": "Phase 2", "range_lo": null, "range_hi": null, "ipo_status": "active"},
  {"year": 2024, "company": "ArriVent Biopharma", "ticker": "AVBP", "date": "2024-03-14", "area": "Oncology (NSCLC)", "offer": 18.0, "proceeds": 175.0, "pricing": "At", "status": "Upsized", "phase": "Phase 2", "range_lo": null, "range_hi": null, "ipo_status": "active"},
  {"year": 2024, "company": "CG Oncology", "ticker": "CGON", "date": "2024-01-26", "area": "Oncology (Bladder)", "offer": 19.0, "proceeds": 380.0, "pricing": "Above", "status": "Upsized", "phase": "Phase 3", "range_lo": null, "range_hi": null, "ipo_status": "active"},
  {"year": 2024, "company": "Kyverna Therapeutics", "ticker": "KYTX", "date": "2024-02-08", "area": "Autoimmune / Cell Therapy", "offer": 22.0, "proceeds": 319.0, "pricing": "Above", "status": "Upsized", "phase": "Phase 1", "range_lo": null, "range_hi": null, "ipo_status": "active"},
  {"year": 2024, "company": "Jupiter Neurosciences", "ticker": "JUNS", "date": "2024-06-05", "area": "Neuroscience", "offer": 4.0, "proceeds": 11.0, "pricing": "Below", "status": "Inline", "phase": "Phase 1", "range_lo": null, "range_hi": null, "ipo_status": "active"},
  {"year": 2024, "company": "Bicara Therapeutics", "ticker": "BCAX", "date": "2024-09-20", "area": "Oncology (EGFR)", "offer": 18.0, "proceeds": 362.0, "pricing": "Above", "status": "Upsized", "phase": "Phase 2", "range_lo": null, "range_hi": null, "ipo_status": "active"},
  {"year": 2024, "company": "MBX Biosciences", "ticker": "MBX", "date": "2024-09-20", "area": "Metabolic / Endocrine", "offer": 16.0, "proceeds": 163.0, "pricing": "At", "status": "Inline", "phase": "Phase 2", "range_lo": null, "range_hi": null, "ipo_status": "active"},
  {"year": 2024, "company": "Zenas BioPharma", "ticker": "ZBIO", "date": "2024-09-20", "area": "Autoimmune", "offer": 17.0, "proceeds": 225.0, "pricing": "At", "status": "Upsized", "phase": "Phase 2", "range_lo": null, "range_hi": null, "ipo_status": "active"},
  {"year": 2024, "company": "Upstream Bio", "ticker": "UPB", "date": "2024-10-11", "area": "Respiratory", "offer": 17.0, "proceeds": 293.0, "pricing": "At", "status": "Upsized", "phase": "Phase 2", "range_lo": null, "range_hi": null, "ipo_status": "active"},
  {"year": 2025, "company": "Ascentage Pharma", "ticker": "AAPG", "date": "2025-01-24", "area": "Oncology", "offer": 17.25, "proceeds": 126.4, "pricing": "Below", "status": "Inline", "phase": "Commercial", "range_lo": null, "range_hi": null, "ipo_status": "active"},
  {"year": 2025, "company": "Metsera", "ticker": "MTSR", "date": "2025-01-30", "area": "Obesity", "offer": 18.0, "proceeds": 316.2, "pricing": "Above", "status": "Upsized", "phase": "Phase 2", "range_lo": 15, "range_hi": 17, "ipo_status": "active"},
  {"year": 2025, "company": "Maze Therapeutics", "ticker": "MAZE", "date": "2025-01-31", "area": "Nephrology", "offer": 16.0, "proceeds": 140.0, "pricing": "At", "status": "Upsized", "phase": "Phase 2", "range_lo": 15, "range_hi": 17, "ipo_status": "active"},
  {"year": 2025, "company": "Sionna Therapeutics", "ticker": "SION", "date": "2025-02-07", "area": "Cystic Fibrosis", "offer": 18.0, "proceeds": 191.0, "pricing": "At Top", "status": "Upsized", "phase": "Phase 2", "range_lo": 16, "range_hi": 18, "ipo_status": "active"},
  {"year": 2025, "company": "Aardvark Therapeutics", "ticker": "AARD", "date": "2025-02-13", "area": "Obesity / Rare", "offer": 16.0, "proceeds": 94.2, "pricing": "Below", "status": "Inline", "phase": "Phase 1", "range_lo": 16, "range_hi": 18, "ipo_status": "active"},
  {"year": 2025, "company": "Advanced Biomed", "ticker": "ADVB", "date": "2025-03-07", "area": "Oncology", "offer": 4.0, "proceeds": 6.6, "pricing": "At", "status": "Inline", "phase": "Preclinical", "range_lo": null, "range_hi": null, "ipo_status": "active"},
  {"year": 2025, "company": "Cuprina Holdings", "ticker": "CUPR", "date": "2025-04-15", "area": "Wound Care", "offer": 4.0, "proceeds": 12.0, "pricing": "At", "status": "Inline", "phase": "Phase 2", "range_lo": null, "range_hi": null, "ipo_status": "active"},
  {"year": 2025, "company": "LB Pharmaceuticals", "ticker": "LBRX", "date": "2025-09-11", "area": "Neuroscience", "offer": 15.0, "proceeds": 285.0, "pricing": "At", "status": "Upsized", "phase": "Phase 2/3", "range_lo": 14, "range_hi": 16, "ipo_status": "active"},
  {"year": 2025, "company": "MapLight Therapeutics", "ticker": "MPLT", "date": "2025-10-27", "area": "CNS", "offer": 17.0, "proceeds": 296.3, "pricing": "At", "status": "Inline", "phase": "Phase 2", "range_lo": null, "range_hi": null, "ipo_status": "active"},
  {"year": 2025, "company": "BillionToOne", "ticker": "BLLN", "date": "2025-11-06", "area": "Diagnostics", "offer": 60.0, "proceeds": 273.1, "pricing": "Above", "status": "Upsized", "phase": "Commercial", "range_lo": null, "range_hi": null, "ipo_status": "active"},
  {"year": 2025, "company": "Evommune", "ticker": "EVMN", "date": "2025-11-06", "area": "Immunology", "offer": 16.0, "proceeds": 172.5, "pricing": "At", "status": "Inline", "phase": "Phase 2", "range_lo": 15, "range_hi": 17, "ipo_status": "active"},
  {"year": 2026, "company": "Aktis Oncology", "ticker": "AKTS", "date": "2026-01-09", "area": "Oncology (Radiopharma)", "offer": 18.0, "proceeds": 365.4, "pricing": "At Top", "status": "Upsized", "phase": "Phase 1b", "range_lo": 16, "range_hi": 18, "ipo_status": "active"},
  {"year": 2026, "company": "Veradermics", "ticker": "MANE", "date": "2026-02-04", "area": "Dermatology", "offer": 17.0, "proceeds": 256.3, "pricing": "Above", "status": "Upsized", "phase": "Phase 3", "range_lo": 14, "range_hi": 16, "ipo_status": "active"},
  {"year": 2026, "company": "Eikon Therapeutics", "ticker": "EIKN", "date": "2026-02-05", "area": "Oncology", "offer": 18.0, "proceeds": 381.0, "pricing": "At Top", "status": "Upsized", "phase": "Phase 1", "range_lo": 16, "range_hi": 18, "ipo_status": "active"},
  {"year": 2026, "company": "AgomAb Therapeutics", "ticker": "AGMB", "date": "2026-02-06", "area": "GI / Immunology", "offer": 16.0, "proceeds": 200.0, "pricing": "At", "status": "Inline", "phase": "Phase 2", "range_lo": null, "range_hi": null, "ipo_status": "active"},
  {"year": 2026, "company": "SpyGlass Pharma", "ticker": "SGP", "date": "2026-02-07", "area": "Ophthalmology", "offer": 16.0, "proceeds": 150.0, "pricing": "At", "status": "Inline", "phase": "Phase 3", "range_lo": null, "range_hi": null, "ipo_status": "active"}
]
